NASDAQ:TVRD
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. reported net income of −$18.2M in fiscal 2025. The diluted share count rose 202.3%.Summary generated from Tvardi Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+202.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 23 | 42 | 21 | 7 | n/a |
| Operating income | −89 | −88 | −121 | −28 | −27 |
| Net income | −88 | −85 | −119 | −29 | −18 |
| Free cash flow | −60 | −79 | −94 | −19 | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KRegulation FD disclosure
Jul 30, 2026 - 8-KOther events
Jul 17, 2026 - 8-KRegulation FD disclosure
Jul 7, 2026 - 4Insider transaction report
Jun 11, 2026 - 4Insider transaction report
Jun 11, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026